

115TH CONGRESS
2D SESSION

H. R. 5980

To authorize, develop, and implement a coordinated tracking system of federally-funded initiatives and grant programs for substance abuse treatment, prevention, and enforcement, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MAY 25, 2018

Mr. ROTHFUS introduced the following bill; which was referred to the
Committee on Oversight and Government Reform

A BILL

To authorize, develop, and implement a coordinated tracking system of federally-funded initiatives and grant programs for substance abuse treatment, prevention, and enforcement, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Coordinated Overdose
5 and Drug Epidemic Response to the Emergency Declara-
6 tion Act” or the “CODE RED Act”.

1 **SEC. 2. AUTHORIZATION, DEVELOPMENT, AND IMPLEMEN-**
2 **TATION OF A COORDINATED TRACKING SYS-**
3 **TEM.**

4 (a) ESTABLISHMENT.—The Director, shall establish
5 a coordinated tracking system of federally-funded initia-
6 tives and grant programs which shall—

7 (1) be the central repository of all relevant
8 grants;

9 (2) identify duplication, overlap, or gaps in
10 funding to provide increased accountability of feder-
11 ally-funded grants for substance abuse treatment,
12 prevention, and enforcement;

13 (3) identify impediments that applicants cur-
14 rently have in the grant application process with ap-
15 plicable agencies; and

16 (4) be developed and maintained by the Office
17 with the support of designated National Drug Con-
18 trol Program Agencies, and any other agency deter-
19 mined by the Director.

20 (b) PERFORMANCE METRICS.—The Director shall
21 identify metrics and achievable goals for grant recipients
22 in furtherance of the Strategy. Such metrics should be
23 used to measure how effective each federally-funded initia-
24 tive is in achieving the objectives of the Strategy and to
25 enable comparisons of federally-funded initiatives to iden-
26 tify those that are the most cost effective.

1 (c) GRANT APPLICATION STANDARDIZATION.—The
2 Director, in consultation with the head of each National
3 Drug Control Program Agency, shall develop a plan for
4 coordinating and standardizing drug control grant appli-
5 cation processes and develop a joint application to be used
6 by all National Drug Control Program Agencies to reduce
7 the administrative burden and improve oversight of Fed-
8 eral funds.

9 (d) CENTRAL PORTAL.—The Director shall maintain
10 on the public, electronic portal of the Office a list all drug
11 control grant award opportunities available in a central
12 location. The head of each National Drug Control Pro-
13 gram Agency shall provide a complete list of all drug con-
14 trol program grant award opportunities to the Director
15 and annually update such list.

16 (e) REPORT TO CONGRESS.—Not later than 180 days
17 after the date of the enactment of this Act, the Director
18 shall submit to Congress a report on progress under this
19 section and the feasibility of block grants of Federal fund-
20 ing to States.

21 (f) DEFINITIONS.—In this section:

22 (1) AGENCY.—The term “agency” has the
23 meaning given the term “executive agency” in sec-
24 tion 102 of title 31, United States Code.

1 (2) DEMAND REDUCTION.—The term “demand
2 reduction” means any activity conducted by a Na-
3 tional Drug Control Program Agency, other than an
4 enforcement activity, that is intended to reduce or
5 prevent the use of drugs or support or provide treat-
6 ment and recovery efforts, including—

7 (A) education about the dangers of illicit
8 drug use;

9 (B) services, programs, or strategies to
10 prevent substance use disorder, including evi-
11 dence-based education campaigns, community-
12 based prevention programs, opioid diversion,
13 collection and disposal of unused prescription
14 drugs, and services to at-risk populations to
15 prevent or delay initial use of an illicit sub-
16 stance;

17 (C) substance use disorder treatment;

18 (D) illicit drug use research;

19 (E) drug-free workplace programs;

20 (F) drug testing, including the testing of
21 employees;

22 (G) interventions for illicit drug use and
23 dependence;

1 (H) expanding availability of access to
2 health care services for the treatment of sub-
3 stance use disorders;

4 (I) international drug control coordination
5 and cooperation with respect to activities de-
6 scribed in this paragraph;

7 (J) pre- and post-arrest criminal justice
8 interventions such as diversion programs, drug
9 courts, and the provision of evidence-based
10 treatment to individuals with substance use dis-
11 orders who are arrested or under some form of
12 criminal justice supervision, including medica-
13 tion assisted treatment;

14 (K) other coordinated and joint initiatives
15 among Federal, State, local, and Tribal agen-
16 cies to promote comprehensive drug control
17 strategies designed to reduce the demand for,
18 and the availability of, illegal drugs;

19 (L) international illicit drug use education,
20 prevention, treatment, recovery, research, reha-
21 bilitation activities, and interventions for illicit
22 drug use and dependence; and

23 (M) research related to any of the activi-
24 ties described in this paragraph.

1 (3) DIRECTOR.—The term “Director” means
2 the Director of the Office of National Drug Control
3 Policy.

4 (4) DRUG CONTROL.—The term “drug control”
5 means any activity conducted by a National Drug
6 Control Program Agency involving supply reduction
7 or demand reduction.

8 (5) ILLICIT DRUG USE; ILLICIT DRUGS; ILLE-
9 GAL DRUGS.—The terms “illicit drug use”, “illicit
10 drugs”, and “illegal drugs” include the illegal or il-
11 licit use of prescription drugs.

12 (6) NATIONAL DRUG CONTROL PROGRAM AGEN-
13 CY.—The term “National Drug Control Program
14 Agency” means any agency (or bureau, office, inde-
15 pendent agency, board, division, commission, sub-
16 division, unit, or other component thereof) that is
17 responsible for implementing any aspect of the Na-
18 tional Drug Control Strategy, including any agency
19 that receives Federal funds to implement any aspect
20 of the National Drug Control Strategy, but does not
21 include any agency that receives funds for drug con-
22 trol activity solely under the National Intelligence
23 Program or the Military Intelligence Program.

24 (7) OFFICE.—The term “Office” means the Of-
25 fice of National Drug Control Policy.

1 (8) STRATEGY.—The term “Strategy” means
2 the National Drug Control Program Strategy.

3 (9) SUPPLY REDUCTION.—The term “supply
4 reduction” means any activity or program conducted
5 by a National Drug Control Program Agency that is
6 intended to reduce the availability or use of illegal
7 drugs in the United States or abroad, including—

8 (A) law enforcement outside the United
9 States;

10 (B) domestic law enforcement;

11 (C) source country programs, including
12 economic development programs primarily in-
13 tended to reduce the production or trafficking
14 of illicit drugs;

15 (D) activities to control international traf-
16 ficking in, and availability of, illegal drugs, in-
17 cluding—

18 (i) accurate assessment and moni-
19 toring of international drug production and
20 interdiction programs and policies; and

21 (ii) coordination and promotion of
22 compliance with international treaties re-
23 lating to the production, transportation, or
24 interdiction of illegal drugs;

1 (E) activities to conduct and promote
2 international law enforcement programs and
3 policies to reduce the supply of drugs;

4 (F) activities to facilitate and enhance the
5 sharing of domestic and foreign intelligence in-
6 formation among National Drug Control Pro-
7 gram Agencies, relating to the production and
8 trafficking of drugs in the United States and in
9 foreign countries;

10 (G) activities to prevent the diversion of
11 drugs for their illicit use; and

12 (H) research related to any of the activi-
13 ties described in this paragraph.

○